United States 116th Congress ✓ Enacted · P.L. 116-291 1 D cosponsors

HR 1966 — Henrietta Lacks Enhancing Cancer Research Act of 2019

Last action — Became Public Law No: 116-291.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed House
  4. ✓
    Passed Senate
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced March 28, 2019. Enacted.

Odds of enactment

High chance

Based on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 52% · moderate confidence

  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (1 D).

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Bill Text

What changed in the latest version

53 added · 55 removed

Plain-language change summary

The amendment adds a note referencing Public Law 116-291 and provides context about Henrietta Lacks and the implications of her tissue being used without consent. It also clarifies the impact of barriers to participating in cancer clinical trials, citing specific reasons why individuals may be unable to join. This change matters because it highlights ethical considerations surrounding informed consent in medical research and emphasizes the significance of improving participation in clinical trials.

→
Previous
Latest
[Congressional Bills 116th Congress] [From the U.S.
[116th Congress Public Law 291] [From the U.S.
Government Publishing Office] [H.R.
Government Publishing Office] [[Page 134 STAT.
1966 Referred in Senate (RFS)] <DOC> 116th CONGRESS 2d Session H.
4894]] Public Law 116-291 116th Congress An Act To direct the Comptroller General of the United States to complete a study on barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials.
R.
<<NOTE:
1966 _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES December 10, 2020 Received;
Jan.
read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ AN ACT To direct the Comptroller General of the United States to complete a study on barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials.
5, 2021 - [H.R.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1.
1966]>> Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, <<NOTE:
Henrietta Lacks Enhancing Cancer Research Act of 2019.>> SECTION 1.
Ultimately, about 1 in cancer clinical trials fail because of lack of patient enrollment.
Ultimately, about 1 in 5 cancer clinical trials fail because of lack of patient enrollment.
(7) Henrietta Lacks and her immortal cells have made a significant contribution to global health, scientific research, quality of life, and patient rights.
[[Page 134 STAT.
4895]] (7) Henrietta Lacks and her immortal cells have made a significant contribution to global health, scientific research, quality of life, and patient rights.
(a) In General.--Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall-- (1) complete a study that-- (A) reviews what actions Federal agencies have taken to help to address barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials, and identifies challenges, if any, in implementing such actions;
(a) <<NOTE:
Deadline.
Reviews.>> In General.--Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall-- (1) complete a study that-- (A) reviews what actions Federal agencies have taken to help to address barriers to participation in federally funded cancer clinical trials by populations that have been traditionally underrepresented in such trials, and identifies challenges, if any, in implementing such actions;
and (2) submit a report to the Congress on the results of such study, including recommendations on potential changes in practices and policies to improve participation in such trials by such populations.
and (2) <<NOTE:
Reports.
Recommenda- tions.>> submit a report to the Congress on the results of such study, including recommendations on potential changes in practices and policies to improve participation in such trials by such populations.
Passed the House of Representatives December 9, 2020.
Approved January 5, 2021.
Attest:
LEGISLATIVE HISTORY--H.R.
CHERYL L.
1966:
JOHNSON, Clerk.
--------------------------------------------------------------------------- CONGRESSIONAL RECORD, Vol.
166 (2020):
Dec.
9, considered and passed House.
Dec.
18, considered and passed Senate.
<all>
⬇ Download PDF
View plain text versions (5)

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  6. Referred to the Subcommittee on Military Personnel.

  7. Referred to the Subcommittee on Health.

  8. ASSUMING FIRST SPONSORSHIP - Mr. Mfume asked unanimous consent that he may hereafter be considered as the first sponsor of H.R. 1966, a bill originally introduced by Representative Cummings, for the purpose of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection.

  9. Mr. Pallone moved to suspend the rules and pass the bill, as amended.

  10. Considered under suspension of the rules. (consideration: CR H7086-7088)

  11. DEBATE - The House proceeded with forty minutes of debate on H.R. 1966.

  12. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

  13. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7086)

  14. Motion to reconsider laid on the table Agreed to without objection.

  15. Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  16. Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.

  17. Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S7829)

  18. Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.

  19. Passed Senate without amendment by Unanimous Consent.

  20. Message on Senate action sent to the House.

  21. Presented to President.

  22. Presented to President.

  23. Signed by President.

  24. Signed by President.

  25. Became Public Law No: 116-291.

  26. Became Public Law No: 116-291.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HR 1966?
HR 1966 is sponsored by Cummings, Elijah E. (Democratic).
What is the current status of HR 1966?
This bill has been enacted into law. Introduced March 28, 2019. Enacted.
Where can I track HR 1966?
Track HR 1966 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 1966

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 1966

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →